Annual Reports

Octapharma Annual Reports provide a comprehensive overview of Octapharma, explaining who we are and what we do. Download the annual reports in English, French, German and Spanish.

Annual Report 2023

Focused. For the Future.

In 2023, Octapharma celebrated 40 years of innovation and success since our company was founded in 1983 by two men with a shared vision to provide haemophilia patients with a safe and efficacious factor VIII therapy.

It was also a year of extraordinary achievement in which we paved the way for future growth with new initiatives to attract donors, build our production capacity, improve productivity and efficiency across our organisation, grow our presence in new markets, and position ourselves as one of the most attractive employers in our industry.

In this year's report, we explore some of the many initiatives currently under way to ensure that Octapharma will build of the successes of the past 40 years and remain a global leader in plasma proteins. This includes a look at how we are transforming our work environment to remain an employer of choice in our industry and are enhancing our production to meet growing global demand for our products.

Maria Isabel from Mexico and Deni from Indonesia share their inspiring stories about how they overcame life-changing conditions, as Octapharma continues to build our presence in new markets. We also look at new initiatives in our critical care portfolio and at how our research and development teams overcame significant challenges to provide new treatment options for patients with von Willebrand disease.

Building on our successes

"It was a year of extraordinary achievement in which we paved the way for future growth."

Delivering strong performance in 2023

"The Octapharma Group once again delivered impressive growth in 2023, with sales up 14.4% over the prior year to a new record of €3.266 billion."

Download the Octapharma Annual Reports in English, French, German and Spanish, which also contain our complete audited financial statements.

Annual Report 2023